+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Aortic Aneurysm - Global Stategic Business Report

  • PDF Icon

    Report

  • 467 Pages
  • April 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 6069907
The global market for Aortic Aneurysm was estimated at US$5.6 Billion in 2024 and is projected to reach US$10.1 Billion by 2030, growing at a CAGR of 10.4% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Aortic Aneurysm market.

Global Aortic Aneurysm Market - Key Trends & Drivers Summarized

Why Is Aortic Aneurysm a Critical Cardiovascular Concern?

Aortic aneurysm is a life-threatening vascular condition characterized by the abnormal dilation or bulging of the aorta, the body`s largest blood vessel. If left untreated, an aortic aneurysm can rupture, leading to severe internal bleeding and a high risk of mortality. The condition is primarily classified into two types: abdominal aortic aneurysm (AAA) and thoracic aortic aneurysm (TAA), with AAA being more prevalent, especially among aging populations. Factors such as hypertension, smoking, high cholesterol, and genetic predisposition contribute significantly to the development of aortic aneurysms. The rise in sedentary lifestyles, obesity, and diabetes is further exacerbating the prevalence of aortic aneurysms globally. Advancements in diagnostic imaging, including computed tomography angiography (CTA), magnetic resonance angiography (MRA), and ultrasound, have significantly improved early detection rates, allowing for timely intervention. However, the asymptomatic nature of the condition in its early stages makes screening programs crucial in high-risk demographics. Governments and healthcare organizations are increasingly focusing on awareness campaigns and routine screening for at-risk individuals, particularly males over 65 and individuals with a family history of aneurysms. The increasing burden of cardiovascular diseases (CVDs) has placed aortic aneurysm management at the forefront of modern cardiology, necessitating continued innovation in early detection, monitoring, and treatment.

How Are Technological Advancements Transforming Aortic Aneurysm Treatment?

Innovations in medical technology have revolutionized the diagnosis, monitoring, and treatment of aortic aneurysms, leading to better patient outcomes and reduced mortality rates. One of the most significant advancements in recent years has been the widespread adoption of endovascular aneurysm repair (EVAR) and thoracic endovascular aneurysm repair (TEVAR) techniques, which have largely replaced traditional open surgical procedures. These minimally invasive procedures involve the placement of stent grafts inside the aorta to reinforce weakened vessel walls, significantly reducing recovery time, hospital stays, and post-operative complications. In addition to procedural innovations, the integration of artificial intelligence (AI) and machine learning (ML) in imaging diagnostics is enhancing the precision and efficiency of aneurysm detection, risk stratification, and surgical planning. Furthermore, 3D printing technology is enabling the creation of patient-specific anatomical models, allowing surgeons to plan and customize interventions with greater accuracy. The introduction of bioresorbable stents, which gradually dissolve after serving their purpose, represents another breakthrough in aneurysm management. Continuous research into next-generation biomaterials and drug-eluting stents is also driving the evolution of aneurysm treatment by improving vascular healing and reducing the risk of complications such as endoleaks. As technological advancements continue to shape the landscape of aortic aneurysm care, personalized medicine and precision treatment strategies are emerging as key trends in the management of this condition.

What Market Trends Are Driving the Demand for Aortic Aneurysm Treatments?

The increasing global prevalence of aortic aneurysms, coupled with advancements in healthcare infrastructure, is driving a significant rise in demand for innovative treatment solutions. One of the most prominent trends shaping the market is the shift toward minimally invasive interventions, with EVAR and TEVAR gaining widespread acceptance as the standard of care due to their lower risk profiles and faster recovery times compared to open surgery. Additionally, the rise of telemedicine and remote monitoring solutions is enabling more effective post-operative care and long-term aneurysm surveillance, reducing the likelihood of complications. The growing adoption of wearable cardiovascular monitoring devices and AI-powered predictive analytics is further improving the management of high-risk patients by allowing for early detection of aneurysm progression. In parallel, regulatory bodies such as the FDA and the European Medicines Agency (EMA) are streamlining approval processes for novel aneurysm repair devices, facilitating faster market entry for next-generation stents and grafts. Emerging economies, particularly in Asia-Pacific and Latin America, are witnessing increased investments in cardiovascular care, leading to greater accessibility to aneurysm screening programs and advanced treatment modalities. Additionally, the growing collaboration between medical device manufacturers, research institutions, and healthcare providers is fostering innovation in aortic aneurysm treatment, paving the way for more efficient, patient-centered solutions.

What Are the Key Growth Drivers Fueling the Aortic Aneurysm Market?

The growth in the aortic aneurysm market is driven by several factors, including technological advancements in stent grafts and minimally invasive procedures, increasing awareness and screening programs, and the rising global burden of cardiovascular diseases. The expanding adoption of EVAR and TEVAR procedures, fueled by their proven benefits in reducing surgical risks and improving patient recovery, is significantly contributing to market expansion. Additionally, the integration of AI-driven diagnostic imaging and predictive analytics is enhancing early detection and treatment planning, leading to better clinical outcomes. The growing demand for patient-specific, customized stent grafts is driving innovation in medical device manufacturing, with 3D printing and advanced biomaterials playing a crucial role in product development. The increasing presence of hybrid operating rooms equipped with cutting-edge imaging technologies is further enabling complex aortic aneurysm procedures to be performed with greater precision and safety. Furthermore, the rising focus on value-based healthcare and cost-effective treatment options is prompting healthcare providers to invest in long-term aneurysm surveillance solutions, including remote monitoring and AI-powered risk assessment tools. The increasing prevalence of lifestyle-related risk factors, coupled with an aging population, is also contributing to a higher incidence of aortic aneurysms, reinforcing the need for continuous advancements in prevention, diagnosis, and treatment. As the market continues to evolve, the convergence of technological innovation, regulatory support, and patient-centered care is expected to drive sustained growth in the global aortic aneurysm treatment landscape.

Report Scope

The report analyzes the Aortic Aneurysm market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.

Segments: Type (Thoracic Aortic Aneurysm, Abdominal Aortic Aneurysm); Treatment (Open Surgical Repair, Endovascular Aneurysm Repair); Product (Stent Grafts, Catheters); End-Use (Hospitals End-Use, Ambulatory Surgery Centers End-Use, Clinics End-Use)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Thoracic Aortic Aneurysm segment, which is expected to reach US$7.2 Billion by 2030 with a CAGR of a 11.7%. The Abdominal Aortic Aneurysm segment is also set to grow at 7.6% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, estimated at $1.5 Billion in 2024, and China, forecasted to grow at an impressive 14.4% CAGR to reach $2.1 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Aortic Aneurysm Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Aortic Aneurysm Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Aortic Aneurysm Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as AbbVie Inc., Aptus Endosystems Inc., B. Braun Melsungen AG, Baxter International Inc., Becton, Dickinson and Company and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 47 Featured):

  • AbbVie Inc.
  • Aptus Endosystems Inc.
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Cardiatis S.A.
  • Cardinal Health Inc.
  • CONMED Corporation
  • Cook Medical Inc.
  • CryoLife Inc.
  • Endologix LLC
  • Endospan Ltd.
  • Getinge AB
  • Johnson & Johnson Services Inc.
  • JOTEC GmbH
  • LeMaitre Vascular Inc.
  • LifeTech Scientific Corporation
  • Lombard Medical Limited
  • Medtronic plc

Tariff Impact Analysis: Key Insights for 2025

Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.

The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.

What’s Included in This Edition:

  • Tariff-adjusted market forecasts by region and segment
  • Analysis of cost and supply chain implications by sourcing and trade exposure
  • Strategic insights into geographic shifts

Buyers receive a free July 2025 update with:

  • Finalized tariff impacts and new trade agreement effects
  • Updated projections reflecting global sourcing and cost shifts
  • Expanded country-specific coverage across the industry

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbbVie Inc.
  • Aptus Endosystems Inc.
  • B. Braun Melsungen AG
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Cardiatis S.A.
  • Cardinal Health Inc.
  • CONMED Corporation
  • Cook Medical Inc.
  • CryoLife Inc.
  • Endologix LLC
  • Endospan Ltd.
  • Getinge AB
  • Johnson & Johnson Services Inc.
  • JOTEC GmbH
  • LeMaitre Vascular Inc.
  • LifeTech Scientific Corporation
  • Lombard Medical Limited
  • Medtronic plc

Table Information